Dr. Maverakis Research Lab
Emanual Maverakis, M.D.
Department of Dermotology, School of Medicine
University of California, Davis
3301 C Street Suite 1400, Sacramento CA 95816
Lab: Institute for Regenerative Cures
2921 Stockton Blvd. Suite 1630
Sacramento, CA 95817
Lab: VA Northern California
10535 Hospital Way, Bldg. 700, #5A031
Rancho Cordova, CA 95655
Dr. Maverakis runs a UC Davis clinic that specializes in the treatment of patients with severe immune-mediated diseases involving the skin. He is also an immunology researcher who holds early career awards from the Howard Hughes Medical Institute and the Burroughs Wellcome Fund.
“In order to gain insight into the pathogenesis of autoimmunity the first step is to identify and characterize the T cells involved.”
Dr. Maverakis became interested in immunology as an undergraduate at the University of California-Los Angeles where he earned departmental honors for his work on a mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis. He then continued his research endeavors at Harvard Medical School (HMS) in Boston where he graduated summa cum laude in 2003. He is in a elite group of only 15 students in over 220 years to have graduated with highest honors from HMS. After completing an internship in internal medicine at Harvard’s Beth Israel Deaconess Medical Center, Dr. Maverakis came to UC Davis to complete a residency in dermatology and in 2007 he joined the faculty. He holds appointments in the Department of Dermatology and in the Department of Medical Microbiology and Immunology. His group is focused on characterizing autoreactive T cell repertoires in humans with immune mediated skin diseases. Such work might lead to better targeted therapies for these types of diseases.
Another focus of the Maverakis lab is to study malignancies that are able induce an immune response. His lab is looking at ways to boost the immune response to the tumor.
His group has published in a variety of journals including the Journal of Clinical Investigation, Proceedings of the National Academy of Sciences, the Journal of Experimental Medicine and Nature Reviews Immunology.
|2007||Howard Hughes Medical Institute Physician-Scientist Early Career Award|
|2007||Burroughs Wellcome Fund Career Award for Medical Scientists|
|2003||M.D. Summa Cum Laude, Harvard Medical School (only 15 awarded in the school’s 215 year history)|
|2009||American Academy of Dermatology Young Investigator Award|
|2008||NIH Career Development Award|
|2006||Chief Resident- UC Davis Department of Dermatology|
|2001-03||Howard Hughes Medical Student Research Fellowship-2 Additional Years of Continued Support (Rarely awarded)|
|2000||Howard Hughes Medical Student Research Fellowship|
|1999-00||Harvard Academic Committee Research Stipend|
|1997||B.S. Summa Cum Laude, University of California Los Angeles|
|1997||Departmental Honors, University of California Los Angeles, Department of Microbio and Mol Genetics|
|1993||Dean’s List (all years), University of California Los Angeles (Awarded for maintaining a 4.0/4.0 G.P.A.)|
Emanual Maverakis, M.D.
Research interests: Immunotherapies for melanoma, T cell mediated skin diseases, and the murine models of autoimmunity, clinical trials for melanoma and autoimmunity
Cutaneous T Cell Lymphoma- We are interested in identifying novel therapeutics that are able to selectively kill malignant T cells.
T cell competition- We are studying the role that T cell competition plays during the evolution of an immune response.
Longitudinal characterization of an autoreactive immune response- We have been able to clearly identify stably expanded T cells longitudinally in patients with chronic autoimmune disease. We are currently characterizing the surface phenotype of these cells.
- Maverakis E, Beech JT, Wilson SS, Quinn A, Pedersen B, and Sercarz EE. T cell receptor CDR3-length analysis reveals the absence of a characteristic public T cell repertoire in neonatal tolerance: the response in the "tolerant" mouse within the residual repertoire is quantitatively similar but qualitatively different. THE JOURNAL OF EXPERIMENTAL MEDICINE 191: (4) 695-702 FEB 2000.
- Maverakis E, Beech J, Stevens DB, et al. Autoreactive T cells can be protected from tolerance induction through competition by flanking determinants for access to class II MHC. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES U.S.A 100 (9): 5342-5347 APR 29 2003.
- Menezes JS, van den Elzen P, Thornes J, Huffman D, Droin N, Maverakis E, and Sercarz EE. Despite clonal dominance by discrete T cell populations which appear as public clonotypes during EAE induction, the entire available repertoire is heterogeneous. JOURNAL OF CLINICAL INVESTIGATION 117(8):2176-85 2007.
- Maverakis E*, Menezes J, Ametani A, Han M, Stevens DB, He Y, Lam KS, Ward ES and Sercarz EE. Mimics induce a non-autoaggressive repertoire which preempts induction of autoimmunity. (*EM corresponding author). PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES U.S.A 2010 9;107(6):2550-5.
- Takada Y, Sagusa J, Mitsiades C, Mitsiades N, Tsai J, He Y, Maningding E, Coleman A, Maverakis D, Rodriquez R, Takada Y and Maverakis E. A T Cell-binding fragment of fibrinogen can prevent autoimmunity. In Press JOURNAL OF AUTOIMMUNITY